SBFI-103

SBFI-103 is a small molecule inhibitor of fatty acid binding protein 5 (FABP5), developed initially by the State University of New York at Albany and further studied by Artelo Biosciences. It acts as a selective FABP5 inhibitor and has demonstrated preclinical efficacy in models of prostate cancer—particularly PTEN-deficient and therapy-resistant forms—as well as in animal models for anxiety and depressive-like behaviors. Mechanistically, inhibition of FABP5 increases intracellular anandamide (AEA) signaling by blocking its transport for degradation, thereby modulating endocannabinoid neurotransmission. Preclinical studies show that SBFI-103 can suppress or eliminate tumors formed from castrate-resistant prostate cancer cells and produce anxiolytic effects when administered to the basolateral amygdala in rats. The drug is being explored for its potential across oncology (notably metastatic castration-resistant prostate cancer), neuropsychiatric disorders such as anxiety and depression, and possibly dermatologic conditions like psoriasis[1][2][3][4][5][7][8].

Other names

SBFI-103SBFI103SBFI 103SB-FI-103SB-FI103SB-FI 103alpha-SBFI-103alpha-SBFI103alpha-SBFI 103